A number of research firms have changed their ratings and price targets for Madrigal Pharmaceuticals (NASDAQ: MDGL):
- 8/4/2026 – Madrigal Pharmaceuticals was upgraded by Wolfe Research from “peer perform” to “outperform”. They now have a $605.00 price target on the stock.
- 8/3/2026 – Madrigal Pharmaceuticals had its price target lowered by Barclays PLC from $964.00 to $962.00. They now have an “overweight” rating on the stock.
- 7/31/2026 – Madrigal Pharmaceuticals had its “buy” rating reaffirmed by UBS Group AG.
- 7/31/2026 – Madrigal Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright.
- 7/31/2026 – Madrigal Pharmaceuticals had its price target lowered by Barclays PLC from $964.00 to $962.00. They now have an “overweight” rating on the stock.
- 7/29/2026 – Madrigal Pharmaceuticals had its price target raised by Canaccord Genuity Group Inc. from $578.00 to $587.00. They now have a “buy” rating on the stock.
- 7/27/2026 – Madrigal Pharmaceuticals is now covered by Wells Fargo & Company. They set an “overweight” rating and a $685.00 price target on the stock.
- 7/27/2026 – Madrigal Pharmaceuticals is now covered by Wells Fargo & Company. They set an “overweight” rating and a $685.00 price target on the stock.
- 7/17/2026 – Madrigal Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 7/17/2026 – Madrigal Pharmaceuticals had its “outperform” rating reaffirmed by Citigroup Inc..
- 6/24/2026 – Madrigal Pharmaceuticals had its “overweight” rating reaffirmed by Piper Sandler.
Insider Buying and Selling at Madrigal Pharmaceuticals
In other news, Director Richard S. Levy sold 5,682 shares of the stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $515.44, for a total value of $2,928,730.08. Following the completion of the transaction, the director owned 22,015 shares in the company, valued at approximately $11,347,411.60. This represents a 20.51% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Soergel sold 1,042 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $495.74, for a total transaction of $516,561.08. Following the transaction, the insider directly owned 10,033 shares of the company’s stock, valued at $4,973,759.42. The trade was a 9.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 7,568 shares of company stock worth $3,880,711 in the last three months. Insiders own 17.60% of the company’s stock.
The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.
See Also
- Five stocks we like better than Madrigal Pharmaceuticals
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Madrigal Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
